STAT3 and neoplasm: Treatment with the covalent STAT3-selective inhibitor PG-S3-009 (Garg et al., 2017) resulted in DFTD tumor cell-specific killing (Figure 3E) and reduced STAT3 phosphorylation of residue Y705 (Figure S4C).